Pressure Grows To Solve Northern Ireland Supply Issues
BGMA Calls For Urgent UK-EU Agreement To Resolve Regulatory Uncertainty
Executive Summary
As political tensions between the UK and EU mount over the Northern Ireland Protocol instigated as part of the pair’s Brexit agreement, the off-patent industry is growing increasingly concerned that regulatory uncertainty will put supply at risk.
You may also be interested in...
EU To Offer Solution To Post-Brexit Regulatory Problems In Northern Ireland
The EU is preparing a formal proposal for ensuring the continued long-term supply of medicines from Great Britain to Northern Ireland from next year, but it will require "enhanced enforcement" by the UK authorities.
Alvotech And Stada Gain Second Ever Higher-Strength Adalimumab Nod
Alvotech and Stada are on the verge of gaining the world’s second ever approval for a higher-strength Humira biosimilar, after the EMA’s CHMP endorsed the firms’ adalimumab under the names Hukyndra and Libmyris at its September meeting.
EU’s Health Emergency Response Plans Must Address Existing Flaws
The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.